Drug Database
Back to search

Japan· JP-4291441A1024

アテゾリズマブ（遺伝子組換え）

A atezolizumab product containing アテゾリズマブ（遺伝子組換え）, registered in Japan by 中外製薬, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

On Japan’s NHI price listATC L01FF05

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedアテゾリズマブ（遺伝子組換え）ATCL01FF05REGISTER NO.JP-4291441A1024PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about アテゾリズマブ（遺伝子組換え）Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Atezolizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FF05 (atezolizumab), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 8 of them publish a price we can compare per daily dose
Search atezolizumab products by name

Atezolizumab · ATC L01FF05

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of atezolizumab costs, country by country.

Normalised to the WHO defined daily dose (89 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Atezolizumab · price per daily dose (89 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$377.53
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
アテゾリズマブ（遺伝子組換え）
Manufacturer
中外製薬
Country
Japan (JP)
ATC code
L01FF05
ATC class
Atezolizumab
Defined daily dose
89 mg, P
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

75 interactions on record for atezolizumab.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check atezolizumab against other medicinesHow interaction checks work

Atezolizumab · interactions on record

75 records

  • 30 severe
  • 45 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atezolizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atezolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tecentriq
  • Liechtenstein · Tecentriq
  • Norway · Tecentriq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8cc2efc-e568-46df-91a4-ecbd723c5d60
GET /v1/drugs/e8cc2efc-e568-46df-91a4-ecbd723c5d60?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１，２００ｍｇ２０ｍＬ１瓶",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "4291441A1024",
  "category": "注射薬",
  "price_yen": 563917,
  "generic_name": "アテゾリズマブ（遺伝子組換え）",
  "product_name_jp": null,
  "therapeutic_class": "4291",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about atezolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console